Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Faii-GyroGlove

Interviews

GyroGlove inventor: the inspiration behind our tremor-reducing glove

Meet the creator of a glove that could restore control of hands

READ MORE

Advances

Giant leap for research as NASA launches Parkinson’s protein into space

LRRK2 protein studied in space could unlock Parkinson’s research

READ MORE
potato with cream of the cream cheese and salted salmon

Recipes & Nutrition

One-day menu for people with Parkinson’s featuring salmon baked potatoes

One-day menu ideas for easy-to-chew meal planning

READ MORE